Hutchmed Regulatory News (HCM)

27 Dec 2007 07:00

Hutchison China Meditech Limited27 December 2007 Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) Block Admission Return London, Thursday, 27 December 2007: Chi-Med announces the following blockadmission return: Name of the company: Hutchison China MediTech Limited Name of the scheme: Hutchison China MediTech Limited Share Option Scheme Period of return: From 26 June 2007 to 26 December 2007 Number and class of securities not issued under the 2,560,606 ordinary shares of US$1 eachscheme at the beginning of the period: Number of securities issued under the scheme during 17,053 ordinary shares of US$1 eachthe period: Balance under the scheme of securities not yet 2,543,553 ordinary shares of US$1 eachissued at the end of the period: Number and class of securities originally admitted 2,560,606 ordinary shares of US$1 each admittedand the date of admission: on 26 June 2007 The total number of securities in issue at the end of the period was 51,229,174 ordinary shares of US$1each. Ends Enquiries Chi-Med Telephone: +852 2121 8200 Christian Hogg, CEO Citigate Dewe Rogerson Telephone: +44 (0) 20 7638 9571 Anthony Carlisle Mobile: +44 (0) 7973 611 888 Yvonne Alexander Mobile: +44 (0) 7866 610 682 About Chi-Med Chi-Med is the holding company of a pharmaceutical and healthcare group basedprimarily in China and was admitted to trading on the Alternative InvestmentMarket of the London Stock Exchange in May 2006. Chi-Med focuses on research,development, manufacture and sale of pharmaceuticals, health supplements andother consumer health and personal care products derived from TraditionalChinese Medicine and botanical ingredients. Chi-Med is majority owned by Hutchison Whampoa Limited, an internationalcorporation listed on the Main Board of The Stock Exchange of Hong Kong Limited. This information is provided by RNS The company news service from the London Stock Exchange